조직공학 시장 보고서 : 유형, 용도, 최종사용자, 지역별(2026-2034년)

The global tissue engineering market size reached USD 22.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 54.1 Billion by 2034, exhibiting a growth rate (CAGR) of 10.09% during 2026-2034. The market is driven by the increasing demand for regenerative medicines and TE procedures, rising incidences of fatal road accidents and trauma injuries, the augmenting need for bone implants among patients, continual technological advancements in the field of three-dimensional (3D) tissue engineering, and rising healthcare expenditure.

TISSUE ENGINEERING MARKET ANALYSIS:

• Major Market Drivers: Continual advancements in biomaterials and stem cell research are driving the market. Besides this, growing demand for regenerative medicine and organ transplants is impelling the market growth. Furthermore, government funding and support for research initiatives are also bolstering market expansion.
• Key Market Trends: The increased use of 3D printing technology in tissue engineering is a significant trend in the market. In line with this, the development of personalized medicine and patient-specific tissue constructs is also gaining momentum. Also, strategic collaborations between research institutions and biotechnology companies are another significant trend in the market.
• Geographical Trends: North America is leading the tissue engineering market growth due to high investment in healthcare research and development. The region's advanced healthcare infrastructure supports market growth. Favorable regulatory frameworks and numerous clinical trials also contribute to North America's dominance.
• Competitive Landscape: Some of the key market players include AbbVie Inc., Becton Dickinson and Company, Episkin, Integra LifeSciences Corporation, Medtronic plc, Organogenesis Inc, ReproCell, Inc., Stryker Corporation, Tissue Regenix Group, Vericel Corporation and Zimmer Biomet.
• Challenges and Opportunities: High costs of tissue engineering procedures and materials pose a significant challenge in the market. In addition to this, ethical concerns and regulatory hurdles remain obstacles to market expansion. However, increasing adoption of regenerative medicine is creating lucrative opportunities in the market.

TISSUE ENGINEERING MARKET TRENDS:

Increasing incidences of chronic diseases

The rising prevalence of chronic diseases, such as cardiovascular disease, diabetes, and orthopedic ailments, has increased the demand for tissue engineering solutions that may repair or replace damaged tissues. Chronic diseases are the leading causes of death and disability worldwide, and they are expected to drive tissue engineering demand throughout the forecast period. Tissue regeneration technology is becoming increasingly popular due to its successful products and low rejection rates. In addition, there is an increasing trend toward more regeneration treatments. Currently, pre-clinical research is focused on the application of tissue-engineered vascular grafts in cardiovascular surgery and treatment. Furthermore, the management of chronic wounds, often resulting from conditions like diabetes, is increasingly utilizing tissue-engineered products to promote faster and more effective healing. Additionally, the rising incidence of chronic respiratory diseases is leading to the development of tissue-engineered lung and airway tissues.

Rapid technological advancements

Technological advancements in the field of 3D tissue engineering, such as the replacement of embryo cells with stem cells, organ-on-a-chip technology, and the use of 3D bioprinters that can efficiently design in vitro implants, are expected to enhance tissue engineering market revenue. In addition, a considerable rise in government funding for medical and academic research activities is anticipated to enhance the growth of the market for tissue engineering throughout the forecast period. The integration of artificial intelligence and machine learning in tissue engineering processes is significantly improving the precision and efficiency of tissue construction. Moreover, collaborations between academic institutions and biotechnology firms are fostering innovation and accelerating the commercialization of advanced tissue-engineered products. For instance, in January 2023, Sartorius, a biopharmaceutical equipment supplier, purchased a 10% investment in 3D bioprinting inventor BICO. Both companies have revealed plans for a collaborative effort.

Rising number of road accidents and trauma injuries

The rising number of road accidents and trauma injuries have been linked to an increase in the development of tissue engineering treatments. This, in turn, is creating a positive tissue engineering market outlook. The number of patients in need of bone implants is increasing as trauma cases and average life spans rise. Approximately 1.19 million lives are lost annually due to road traffic crashes. According to the World health Organization (WHO), between 20 and 50 million more people suffer non-fatal injuries, with many incurring a disability. These injuries require medical procedures, resulting in an increasing demand for novel tissue engineering options. The prevalence of road traffic accidents has necessitated advancements in tissue engineering to address complex injury repair. Consequently, healthcare providers are increasingly adopting tissue-engineered products to enhance recovery outcomes and reduce complications associated with traditional treatments. Additionally, the growing geriatric population, which is more susceptible to trauma injuries, further amplifies the need for innovative tissue engineering solutions in the medical field.

TISSUE ENGINEERING MARKET SEGMENTATION:

Breakup by Type:

• Synthetic Scaffold Material
• Biologically Derived Scaffold Material
• Others

Biologically derived scaffold material dominates the market

The tissue engineering market overview shows that the biologically derived scaffold material is leading the market. Biologically derived scaffolds offer superior biocompatibility and mimic the natural extracellular matrix, promoting better cell attachment, proliferation, and differentiation. This enhances the overall effectiveness of tissue regeneration processes. These materials include naturally occurring polymers including collagen, gelatin, hyaluronic acid, chitosan , and alginate, as well as decellularized extracellular matrix (ECM) scaffolds which are more readily accepted by the body's immune system, reducing the risk of rejection and inflammatory responses compared to synthetic materials. Consequently, the growing preference for these biologically derived materials among researchers and clinicians is resulting in their prominence in the market.

Breakup by Application:

• Orthopedics and Musculoskeletal
• Neurology
• Cardiovascular
• Skin and Integumentary
• Dental
• Others

Orthopedics and musculoskeletal hold the largest share in the market

The orthopedics and musculoskeletal segment held the highest revenue share during the tissue engineering market forecast period, due to the rising frequency of musculoskeletal illnesses. Furthermore, tissue engineering has emerged as an important therapy option for orthopedic surgeons in the management of various musculoskeletal problems, including meniscal deficiencies in young athletes and osteochondral abnormalities in the glenohumeral joint. According to the World Health Organization (WHO), rheumatoid arthritis affects over 23 million individuals globally. Additionally, significant investments in research and development for orthopedic applications, coupled with technological advancements in biomaterials and regenerative medicine, have led to the introduction of highly effective tissue-engineered products, thereby contributing to growth in this segment.

Breakup by End User:

• Hospitals and Clinics
• Ambulatory Facilities

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest tissue engineering market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for tissue engineering.

North America dominated the market and accounted for the majority of tissue engineering market recent developments, due to the rising awareness regarding stem cell therapy, a growing elderly population, and an increase in chronic illness incidence. Furthermore, sophisticated technology for diagnosing and treating chronic illnesses, the availability of private and government funding, and high healthcare spending are among the factors contributing to its significant proportion. Advancements in 3D tissue engineering technology, as well as the presence of notable market participants, are key drivers of growth through continual product introductions. Moreover, numerous innovations in 3D bioprinting and the expansion of medical tourism are propelling the growth of the market in this region and offering numerous tissue engineering market recent opportunities.

Competitive Landscape:

The market is extremely competitive, with many companies competing for the majority of the market share. They are investing heavily in research and development to innovate and improve tissue engineering technologies, focusing on the creation of advanced biomaterials and scaffolds that enhance tissue regeneration and integration. Additionally, collaborations and partnerships with academic institutions, biotechnology firms, and healthcare providers are being established to leverage diverse expertise and accelerate product development. Moreover, several tissue engineering companies are also focusing on upgrading their product portfolios in order to meet the current demand. To meet the growing demand, they are also scaling up their manufacturing capabilities and optimizing production processes for cost-efficiency and higher output.

The report provides a comprehensive analysis of the competitive landscape in the global tissue engineering market with detailed profiles of all major companies, including:

• AbbVie Inc.
• Becton Dickinson and Company
• Episkin
• Integra LifeSciences Corporation
• Medtronic plc
• Organogenesis Inc
• ReproCell, Inc.
• Stryker Corporation
• Tissue Regenix Group
• Vericel Corporation
• Zimmer Biomet

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global tissue engineering market in 2025?

2. What is the expected growth rate of the global tissue engineering market during 2026-2034?

3. What are the key factors driving the global tissue engineering market?

4. What has been the impact of COVID-19 on the global tissue engineering market?

5. What is the breakup of the global tissue engineering market based on the type?

6. What is the breakup of the global tissue engineering market based on the application?

7. What are the key regions in the global tissue engineering market?

8. Who are the key players/companies in the global tissue engineering market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Tissue Engineering Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Synthetic Scaffold Material
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Biologically Derived Scaffold Material
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Orthopedics and Musculoskeletal
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Neurology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Cardiovascular
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Skin and Integumentary
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Dental
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Facilities
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AbbVie Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Becton Dickinson and Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Episkin
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Integra LifeSciences Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Medtronic plc
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Organogenesis Inc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 ReproCell, Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Stryker Corporation
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Tissue Regenix Group
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Vericel Corporation
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Zimmer Biomet
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis